Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants Mar 24, 2022
COMPASS Pathways And Partners Launch The Centre For Mental Health Research And Innovation, In The UK Mar 24, 2022
Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules Feb 17, 2022
Therapsil CEO Spencer Hawkswell Speaks To Health Canada’s Intent To Deny Section 56 Exemptions To Healthcare… Feb 9, 2022
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of… Feb 9, 2022